Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.7%

8 terminated out of 75 trials

Success Rate

80.5%

-6.0% vs benchmark

Late-Stage Pipeline

19%

14 trials in Phase 3/4

Results Transparency

9%

3 of 33 completed with results

Key Signals

3 with results80% success

Data Visualizations

Phase Distribution

49Total
Not Applicable (20)
P 1 (3)
P 2 (12)
P 3 (9)
P 4 (5)

Trial Status

Completed33
Unknown13
Recruiting9
Terminated8
Withdrawn5
Not Yet Recruiting4

Trial Success Rate

80.5%

Benchmark: 86.5%

Based on 33 completed trials

Clinical Trials (75)

Showing 20 of 20 trials
NCT06155812Phase 2CompletedPrimary

Multimodal Vasopressor Strategy in Septic Shock

NCT04569942Phase 3Active Not RecruitingPrimary

Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis

NCT06426407TerminatedPrimary

Vasopressin Hemodynamic Response as a Septic Shock Subphenotype Indicator

NCT06217939Not ApplicableRecruiting

Early Intravenous Hydrocortisone in Sepsis

NCT04178148Not ApplicableCompletedPrimary

Personalized Dose Optimization of Amikacin Guided by Pharmacokinetic Modeling Software in Patients With Septic Shock

NCT06727318Completed

Comparison of Peripheral Perfusion Indicators and Lactate Levels

NCT03663192CompletedPrimary

Strain Echocardiography During Septic Shock : an Observational Pilot Study

NCT01231672CompletedPrimary

Prospective Validation of Clini-biological Parameters Including Initial Hemostasis, Which Improve the Prediction of Death at 1 Month Among Patients With Septic Shock

NCT05591924Recruiting

Early Severe Illness TrAnslational BioLogy InformaticS in Humans

NCT02664753Phase 3Terminated

L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury

NCT05931601Phase 3Recruiting

Early Initiated Vasopressor Therapy in the Emergency Department

NCT04934943Not Yet Recruiting

"Mini Fluid Challenge Assessment: a Comparison Among Three Hemodynamic Tools"

NCT04114162Completed

Fluid Overload Quantification in Septic Shock

NCT04750070Phase 3Recruiting

Management of Shock in Children With SAM or Severe Underweight and Diarrhea

NCT03643367Phase 2Not Yet RecruitingPrimary

Sevoflurane Sedation in Patients With Septic Shock

NCT06786364RecruitingPrimary

Types of Photoplethysmographic Waves in Adult Patients with Septic Shock

NCT03592693Phase 2TerminatedPrimary

Vitamin C, Hydrocortisone and Thiamine for Septic Shock

NCT06062303Not ApplicableRecruiting

Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2

NCT05990491RecruitingPrimary

Pituitary Function After Recovery From Septic Shock Among ICU Survivors

NCT03158948Phase 2CompletedPrimary

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock

Scroll to load more

Research Network

Activity Timeline